CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CytRx Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CytRx Corporation
11726 San Vicente Blvd Ste 650
Phone: (310) 826-5648p:310 826-5648 LOS ANGELES, CA  90049-5079  United States Ticker: CYTRCYTR

Business Summary
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Steven A.Kriegsman 77 5/3/2018 7/1/2002
President, Chief Operating Officer Eric L.Curtis 51 5/3/2018 5/3/2018
Director Earl W.Brien 58 12/2/2016 12/2/2016
Director Joel K.Caldwell 63 7/12/2017 7/12/2017
Independent Director Louis J.Ignarro 77 7/24/2002 7/24/2002

Subsidiaries
Business Name Address City State/Province Country
INNOVIVE Pharmaceuticals, Inc. 555 Madison Avenue New York NY United States

Business Names
Business Name
CYTR
GGC Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc.

General Information
Number of Employees: 6 (As of 3/29/2019)
Outstanding Shares: 33,637,501 (As of 9/30/2019)
Shareholders: 282
Stock Exchange: OTC
Federal Tax Id: 581642740
Fax Number: (310) 826-6139
Email Address: webmaster@cytrx.com


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 14, 2019